12 years after going public, beleaguered gene therapy company bluebird bio will be sold to private equity groups Carlyle and ...

Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...

Exclusive: Mass General Brigham’s Gene and Cell Therapy Institute is partnering with Cambridge biotech Cellino to create the ...